anti- CD97 antibody

Background

Adhesion G protein-coupled receptor E5 (ADGRE5), also known as CD97, is a member of the adhesion GPCR family and plays an essential role in cell-cell and cell-matrix interactions. ADGRE5 is highly expressed in immune cells, including macrophages, neutrophils, and T-cells, as well as in endothelial and epithelial cells, where it mediates adhesion, migration, and cellular activation. It is a heterodimeric receptor that interacts with extracellular matrix proteins and cellular ligands such as CD55 (decay-accelerating factor), enabling immune surveillance and inflammation regulation. ADGRE5 is upregulated during inflammation, infection, and cancer progression, contributing to leukocyte recruitment, angiogenesis, and metastasis. Dysregulation of ADGRE5 is associated with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease, and its expression levels are linked to tumor aggressiveness in cancers like glioblastoma and colorectal cancer. Therapeutic targeting of ADGRE5 is being explored as a strategy to modulate immune responses and inhibit tumor metastasis by disrupting its signaling pathways and ligand interactions.